A 38-year-old woman with a 3-year history of erosive esophagitis is maintained on pantoprazole 40 mg once daily. She reports breakthrough symptoms (heartburn and regurgitation) 3–4 times per week and denies NSAID use or H. pylori infection. Repeat upper endoscopy shows persistent grade II erosive changes. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has erosive esophagitis with breakthrough symptoms despite standard-dose PPI monotherapy. The persistence of endoscopic erosions indicates inadequate acid suppression. ## PPI Dose Optimization Strategy **Key Point:** Erosive esophagitis requires more aggressive acid suppression than non-erosive GERD. Approximately 20–30% of patients require twice-daily PPI dosing for adequate symptom control and mucosal healing. **High-Yield:** Dosing strategy for erosive esophagitis: - **Mild erosive disease:** Standard-dose PPI once daily (e.g., pantoprazole 40 mg OD) - **Moderate-to-severe erosive disease or breakthrough symptoms:** PPI twice daily (e.g., pantoprazole 40 mg BD) - **Refractory disease:** Consider H₂-blocker addition or switch to alternative PPI ## Comparison of Acid Suppression Strategies | Strategy | Acid Suppression | Healing Rate (Erosive) | Indication | |----------|------------------|------------------------|------------| | **PPI once daily** | ~90% | 70–80% | Mild erosive, non-erosive GERD | | **PPI twice daily** | >95% | >90% | Moderate-to-severe erosive, breakthrough symptoms | | **PPI + H₂ blocker** | ~95% | >90% | Refractory, severe disease | | **Fundoplication** | N/A (surgical) | >90% long-term | Failed medical therapy, young patient, poor compliance | ## Management Algorithm for Refractory Erosive Esophagitis ```mermaid flowchart TD A[Erosive esophagitis on standard PPI]:::outcome --> B{Breakthrough symptoms?}:::decision B -->|Yes| C{Endoscopic healing?}:::decision C -->|No healing| D[Increase PPI to twice daily]:::action C -->|Partial healing| D D --> E[Reassess endoscopy at 4-8 weeks]:::action E --> F{Healed?}:::decision F -->|Yes| G[Continue twice-daily PPI]:::action F -->|No| H[Add H2 blocker or switch PPI]:::action H --> I[Reassess at 4 weeks]:::action I --> J{Refractory?}:::decision J -->|Yes| K[Consider fundoplication if young/motivated]:::action J -->|No| L[Continue optimized medical therapy]:::action ``` **Clinical Pearl:** Twice-daily PPI dosing increases intragastric pH to >4 for >16 hours per day, compared to ~12 hours with once-daily dosing. This is critical for healing erosive lesions, which require sustained acid suppression. ## Why Other Options Are Suboptimal - **Adding ranitidine:** H₂ blockers have a ceiling effect and are inferior to PPI monotherapy for erosive esophagitis. This combination is less effective than PPI dose escalation and adds unnecessary polypharmacy. - **Switching to omeprazole:** Different PPIs (omeprazole, lansoprazole, pantoprazole, esomeprazole) have similar efficacy when dosed appropriately. Switching without dose optimization is unlikely to improve outcomes and delays effective therapy. - **Fundoplication:** Surgical intervention is reserved for patients who have failed optimized medical therapy (including twice-daily PPI ± H₂ blocker), are young with excellent operative candidacy, or have poor medication compliance. This patient has not yet been optimized medically.